Navigation Links
Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
Date:6/22/2011

NUTLEY, N.J. and BASEL, Switzerland, June 22, 2011 /PRNewswire/ -- The Roche manuscript: "Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies" has been published in the prestigious Proceedings of the National Academy of Sciences of the USA (PNAS). Corresponding authors are Wolfgang Schaefer, Research Leader Molecular Biology in Biologics Research at Penzberg, and Christian Klein, Head of Oncology Programs, Discovery Oncology at Roche Glycart. Both are part of Roche's Pharma Research and Early Development (pRED) organization.  

"It is encouraging to us that PNAS reviewers recognized the novelty of the approach for the generation of human bispecific, bivalent antibodies," note Wolfgang Schaefer and Christian Klein. "This technological breakthrough from pRED allowing generation and production of bispecific bivalent IgG antibodies that are very similar to conventional IgGs will prove a formidable benefit to patients."

The published paper describes a novel and generic approach to convert two given antibodies to human bivalent bispecific IgG antibodies that behave like standard monoclonal IgG antibodies in terms of target binding, stability and pharmacokinetics.

"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies", PNAS online Early Edition (EE), http://www.pnas.org/content/early/recent.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
2. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
5. Ikaria® To Present at 2011 BIO Business Forum and International Convention
6. Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor
7. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
8. Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes
9. MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.
10. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
11. BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 Biostage, Inc. (Nasdaq: ... bioengineered organ implants to treat cancers and other life-threatening ... that Jim McGorry, CEO of Biostage, will ... panel at the MassBio 2017 Annual Meeting ... in Cambrige, Massachussetts. The 3D Printing and BioEngineering ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
(Date:3/27/2017)... Branford, Connecticut (PRWEB) , ... March 27, 2017 ... ... company dedicated to accelerating the fight against cancer, autoimmune disease and more through ... to the single-cell metabolomics and proteomics analysis platform developed in the laboratory ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):